Would you switch to TDM-1 in the adjuvant setting in HER-2 positive breast cancer patients with residual disease after neoadjuvant chemotherapy if neoadjuvant chemotherapy did not include anthracyclines?  

Only a small subset (22-24%) of patients in Katherine trial received a non-anthracycline containing regimen.

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Wenatchee Valley Med Center
So far, insurance companies in my area are not app...
Sign in or Register to read more